1. Home
  2. MEIP vs OMH Comparison

MEIP vs OMH Comparison

Compare MEIP & OMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • OMH
  • Stock Information
  • Founded
  • MEIP 2000
  • OMH 2015
  • Country
  • MEIP United States
  • OMH Singapore
  • Employees
  • MEIP N/A
  • OMH N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • OMH Real Estate
  • Sector
  • MEIP Health Care
  • OMH Finance
  • Exchange
  • MEIP Nasdaq
  • OMH Nasdaq
  • Market Cap
  • MEIP 13.3M
  • OMH 13.6M
  • IPO Year
  • MEIP 2003
  • OMH 2023
  • Fundamental
  • Price
  • MEIP $2.80
  • OMH $1.52
  • Analyst Decision
  • MEIP Hold
  • OMH Hold
  • Analyst Count
  • MEIP 1
  • OMH 1
  • Target Price
  • MEIP N/A
  • OMH N/A
  • AVG Volume (30 Days)
  • MEIP 13.3K
  • OMH 5.4M
  • Earning Date
  • MEIP 05-13-2025
  • OMH 07-07-2025
  • Dividend Yield
  • MEIP N/A
  • OMH N/A
  • EPS Growth
  • MEIP N/A
  • OMH N/A
  • EPS
  • MEIP N/A
  • OMH N/A
  • Revenue
  • MEIP N/A
  • OMH $7,976,578.00
  • Revenue This Year
  • MEIP N/A
  • OMH $28.40
  • Revenue Next Year
  • MEIP N/A
  • OMH $23.07
  • P/E Ratio
  • MEIP N/A
  • OMH N/A
  • Revenue Growth
  • MEIP 33.76
  • OMH 117.53
  • 52 Week Low
  • MEIP $1.46
  • OMH $0.59
  • 52 Week High
  • MEIP $4.10
  • OMH $6.20
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 78.43
  • OMH 46.11
  • Support Level
  • MEIP $2.21
  • OMH $1.45
  • Resistance Level
  • MEIP $2.95
  • OMH $1.59
  • Average True Range (ATR)
  • MEIP 0.15
  • OMH 0.40
  • MACD
  • MEIP 0.05
  • OMH 0.02
  • Stochastic Oscillator
  • MEIP 81.48
  • OMH 35.76

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

Share on Social Networks: